Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Jaguar Animal Health, Inc. on May 8, 2017. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Three proposals were submitted to and approved by stockholders:
- Election of Directors: Stockholders elected Jiahao Qiu and John Micek III as Class II directors for a three-year term ending in 2020.
- Ratification of Auditors: Stockholders ratified the selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Stock Issuance Approval: Stockholders approved the issuance of additional shares of common stock to Aspire Capital Fund LLC pursuant to a common stock purchase agreement dated June 8, 2016, in compliance with Nasdaq Listing Rule 5635(d).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the terms of the common stock purchase agreement with Aspire Capital Fund LLC to understand the dilution impact of the approved share issuance.
- Confirm the background and qualifications of the newly elected directors, Jiahao Qiu and John Micek III.
- Review the full Proxy Statement referenced in the filing for detailed descriptions of the proposals and voting procedures.